Papers/PMID:30081859
Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).
BMC neurology2018The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
melatonin — no detected effect on nocturnal voiding frequency (nocturia)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There was no significant change seen with melatonin for the primary outcome measure, the number of nocturnal episodes per night.”
Quoted verbatim from Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).. - Study
- crossover
- Duration
- 6 weeks
- Dose
- 2 mg sustained-release melatonin (Circadin) orally at bedtime, 6 weeks per phase
- Population
- 31 randomised adults with multiple sclerosis and nocturia (26 completed); placebo-controlled crossover, 6 weeks per phase; nocturia episodes from the ICIQ bladder diary
Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).2018PMID:30081859An author is affiliated with a producerPermalink